January 27, 2021
Business News

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

CAMBRIDGE, Mass.–()–Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form of arsenic trioxide (ATO). SY-2101 represents a strategic opportunity to leverage Syros’ expertise and capabilities to advance its growing footprint in hematologic disorders, with a targeted clinical-stage drug candidate that has the potential to dramatically reduce the treatment burden of a standard-of-care regimen for newly diagnosed acute promyelocytic leukemia (APL).

“It’s rare to talk about cures in cancer,” said Nancy…

Click here to view the original article.

Related Posts

You might also like ...

Jyske Bank sceglie IDEMIA per il lancio della prima carta di pagamento della Danimarca in plastica riciclata
TeleSign Board Appoints Joseph Burton as CEO
AON Splash Image
Enviva Partners, LP Announces Twenty-Second Consecutive Distribution Increase